Difference between revisions of "Ancillary testing in prostate cancer"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
'''Ancillary testing in prostate cancer''' is evolving. ''Prostate cancer panel'' redirect here. | '''Ancillary testing in prostate cancer''' is evolving. ''Prostate cancer panel'' redirect here. | ||
==PARP inhibitors== | |||
*Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib, target BRCA1/2 mutations.<ref name=pmid28250726>{{cite journal |authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A |title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |journal=Prz Menopauzalny |volume=15 |issue=4 |pages=215–219 |date=December 2016 |pmid=28250726 |pmc=5327624 |doi=10.5114/pm.2016.65667 |url=}}</ref> | |||
Molecular panel: | |||
*BRCA1 | |||
*BRCA2 | |||
*ATM | |||
*PALB2 | |||
==See also== | ==See also== | ||
Revision as of 15:09, 1 November 2022
Ancillary testing in prostate cancer is evolving. Prostate cancer panel redirect here.
PARP inhibitors
- Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib, target BRCA1/2 mutations.[1]
Molecular panel:
- BRCA1
- BRCA2
- ATM
- PALB2
See also
References
- ↑ Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (December 2016). "PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting". Prz Menopauzalny 15 (4): 215–219. doi:10.5114/pm.2016.65667. PMC 5327624. PMID 28250726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/.